BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:rilzabrutinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of rilzabrutinib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07216079-1477@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT07216079)
DESCRIPTION:rilzabrutinib\, phase 3\, Immune Thrombocytopenia.\nStudy: Rilz
 abrutinib for the Adult Participants With Chronic ITP Who Have Completed P
 hase 3 Study in Japan\nEstimated primary completion: 25 November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rilzabrutinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07216079
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500702-1477@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:rilzabrutinib: Phase 2 readout est. (NCT06500702)
DESCRIPTION:rilzabrutinib\, phase 2.\nStudy: A Study to Evaluate the Effica
 cy and Safety of Frexalimab\, Brivekimig\, or Rilzabrutinib in Participant
 s Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or M
 inimal Change Disease\nEstimated primary completion: 23 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rilzabrutinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06500702
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06984627-1477@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:rilzabrutinib: Phase 2 readout est. (NCT06984627)
DESCRIPTION:rilzabrutinib\, phase 2.\nStudy: A Study to Investigate the Eff
 icacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disea
 se\nEstimated primary completion: 11 February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/rilzabrutinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06984627
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07853131-1477@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270421
DTEND;VALUE=DATE:20270422
SUMMARY:rilzabrutinib: Phase 1 readout est. (NCT07853131)
DESCRIPTION:rilzabrutinib\, phase 1.\nStudy: Study to Assess the Plasma Con
 centration of Rilzabrutinib Given as a Tablet to Adult Participants With S
 evere Renal Impairment Compared to Matched Participants With Normal Renal 
 Function\nEstimated primary completion: 21 April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rilzabrutinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07853131
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975865-1477@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270723
DTEND;VALUE=DATE:20270724
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT06975865)
DESCRIPTION:rilzabrutinib\, phase 3.\nStudy: The Efficacy and Safety of Ril
 zabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease\nE
 stimated primary completion: 23 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rilzabrutinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06975865
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007962-1477@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT07007962)
DESCRIPTION:rilzabrutinib\, phase 3\, Immune Thrombocytopenia.\nStudy: Stud
 y to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With
  Immune Thrombocytopenia (ITP) Who Failed First-line Treatment\nEstimated 
 primary completion: 5 November 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rilzabrutinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07007962
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07086976-1477@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT07086976)
DESCRIPTION:rilzabrutinib\, phase 3.\nStudy: A Study to Investigate the Eff
 icacy\, Safety\, and Pharmacokinetics of Oral Rilzabrutinib Compared With 
 Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hem
 olytic Anemia\nEstimated primary completion: 31 May 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rilzabrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07086976
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190196-1477@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280628
DTEND;VALUE=DATE:20280629
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT07190196)
DESCRIPTION:rilzabrutinib\, phase 3.\nStudy: A 52-week Study of Rilzabrutin
 ib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-r
 elated Disease\nEstimated primary completion: 28 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rilzabrutinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07190196
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923305-1477@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20350510
DTEND;VALUE=DATE:20350511
SUMMARY:rilzabrutinib: Phase 2/3 readout est. (NCT07923305)
DESCRIPTION:rilzabrutinib\, phase 2/3.\nStudy: Phase 2 and 3 Placebo Contro
 lled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to 
 Evaluate Efficacy\, Safety\, and Tolerability\nEstimated primary completio
 n: 10 May 2035. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilza
 brutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07923305
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
